Waning Humoral Response 6 Months after SARS-CoV-2 Vaccination with the Mrna-Bnt162b2 Vaccine in Hemodialysis Patients: Time for a Boost

We and others have found a high short-term seroconversion rate between 71% and 98% in hemodialysis patients following a complete 2-dose vaccination course with the mRNA-BNT162b2 vaccine (Pfizer–BioNTech).1,2 After natural infection, 76% of hemodialysis patients remained seropositive after a median time period of 124 days after infection.3 However, to our knowledge, there are no serial data available on the maintenance of the vaccine-induced severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) humoral response in hemodialysis patients.